Publication Announcement: “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis"

The U.S. Centers for Disease Control and Prevention (CDC) Tuberculosis Trials Consortium (TBTC), together with collaborators from the National Institutes of Health’s (NIH) AIDS Clinical Trial Group (ACTG), is pleased to announce the publication of “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis" in the New England Journal of Medicine.

The article details findings from study 31/A5349 – an international, randomized, controlled, open label, phase 3 non-inferiority clinical trial. The trial demonstrated that a shorter four-month daily treatment regimen with high-dose (“optimized”) rifapentine and moxifloxacin is as effective as (non-inferior to) the standard daily six-month regimen in curing drug-susceptible tuberculosis (TB) disease. This is the first successful short treatment regimen for drug-susceptible TB disease identified in almost 40 years. The availability of shorter regimens enables patients to be cured faster, and has the potential to reduce treatment costs, improve patient quality of life, and increase completion of therapy.  CDC will use the results of this study to help inform future TB disease treatment guidelines, innovations for designing future clinical trials, and our work with TB programs and clinicians to improve available treatment regimens for TB disease. 

Dr. April Pettitwas a member of the TBTC protocol team. 

Click here to access the article on PubMed!!